ESPEN 2013 - Late breaking abstract submission

Late Breaking Abstract

ESPEN13-1801

EFFECT OF EPA-ENRICHED DIETARY SUPPLEMENT IN PATIENTS WITH EXACERBATION OF COPD ON LEAN BODY MASS MAINTENANCE

T. Ogasawara ^1,*S. Marui ²Y. Okamoto ²M. Ohgiku ³Y. Ikematsu ³

¹Respiratory medicine, ²Nutrition department , ³Surgery, HAMAMATSU MEDICAL CENTER, Hamamatsu, Japan

Rationale: Cachexia of patient with chronic obstructive pulmonary disease (COPD) is thought to be mediated by systemic inflammation. Both frequency of exacerbation and lean body mass (LBM) depletion are independently associated with excess mortality. We aimed to evaluate the effect of eicosapentaenoic acid (EPA) enriched dietary supplement in patients with exacerbation of COPD on prevention of LBM depletion during corticosteroid therapy.

Methods: We performed a prospective study of 12 patients with exacerbation of COPD requiring admission to our hospital between June 2012 and March 2013. LBM index (LBMI, LBM/height²) was measured using a bioelectrical impedance analyzer (InBody730) before the start of EPA-enriched supplement (ProSure^®) and at the time of discharge. Pulmonary rehabilitation was performed to all patients during hospitalization.

Results: The mean age was 79.6 years old (range, 69 to 91), gender: 11 males/1 females. The mean (SD) body mass index (BMI) and FEV1 were 19.9 (3.8) kg/m² and 55.0 (26.0) %predicted. Three patients discontinued EPA-enriched supplement for their own personal reason, therefore we divided patients into EPA group (n = 9) and control group (n = 3). There were no significant differences in severity of COPD, the dosage amount of systemic corticosteroid therapy, or hospital length of stay between these two groups.LBMI in control group decreased significantly as 15.8 ± 1.8 to 15.3 ± 2.0 kg/m² (p = 0.04), however LBMI in EPA group was maintained during hospitalization (15.7 ± 2.8 to 15.7 ± 2.6 kg/m², p = 0.86). There was a significant decrease in skeletal muscle mass (- 0.83 ± 0.25 kg, p = 0.03) only in control group.

Conclusion: EPA-enriched dietary supplement in patients with exacerbation of COPD might prevent LBM depletion induced by corticosteroid therapy.

Disclosure of Interest: None Declared

Keywords: COPD